Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05468905
Other study ID # wulab-CLACIS
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 10, 2021
Est. completion date December 2026

Study information

Verified date July 2022
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact Qing-Qing Tao, M.D.
Phone 13777820430
Email qingqingtao@zju.edu.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a multi-center longitudinal study that consists of five cohorts: cognitive normal aging (CN), Subjective cognitive impairment (SCI), mild cognitive impairment (MCI), Alzheimer's disease (AD) and vascular cognitive impairment (VCI). The goals of this study are as follow: 1.To establish longitudinal cohort study database containing comprehensive epidemiological data, neuropsychological test data, laboratory parameters, image data and biological samples. 2. To determine the risk factors of AD and other dementias. 3. To explore the conversion rates from CN to SCI, MCI or AD and the risk factors as well as biomarkers for the progression from CN to SCI, MCI or AD. 4. To explore and validate blood, CSF, urine, imaging and other biomarkers for the early detection and progression of AD.


Description:

As the population ages in China, the number of patients with neurocognitive disorders such as Alzheimer's disease (AD) and vascular cognitive impairment (VCI) is steadily increasing. The burden of cognitive impairment in China has been an important public health problem. Cohort study on aging and cognitive impairment is urgent to better understand and address this issue. Early prevention, diagnosis and treatment are critical for reduction the burden of cognitive impairment. In this prospective study, subjects will be recruited into one of the five groups based on inclusion and exclusion criteria: 1) CN, 2) MCI 3) AD and 4) VCI. Each of the subjects will be followed up at designated time points up to 5 years. Epidemiological data, medical, imaging (MRI and PET scans), genetic information and various biological samples will be collected during the baseline and follow-up period.


Recruitment information / eligibility

Status Recruiting
Enrollment 4000
Est. completion date December 2026
Est. primary completion date December 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years to 99 Years
Eligibility Inclusion Criteria: Inclusion Criteria: 1. Cognitive normal aging (CN) 1. 40 years and older , without cognitive impairment, MMSE=22 2. Informed consent is signed by the participant 2. Subjective cognitive impairment (SCI) Participants aged 40 and older, with absence of dementia (by DSM IV and DSM V) criteria. Normal age-, sex-, and education-adjusted performance on standardized cognitive tests, which are used to classify mild cognitive impairment (MCI) or prodromal AD. Self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event. Answering "yes" to both of the following questions: "Do you feel like your memory or thinking is becoming worse?" and "Does this concern you?" 3. Mild cognitive impairment (MCI) 1. 40 years and older 2. Diagnosis according to 2004 Peterson's MCI criteria. 3. Clinical Dementia Rating (CDR) = 0.5. 4. Memory loss is prominent, and may also be with other cognitive domain impairment. 5. Insidious onset, slow progress. 4. Alzheimer's disease (AD) 1. 50 years and older 2. Dementia is diagnosed according to the criteria described by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-R). The diagnosis of AD according to the National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS- ADRDA) or National Institute on Aging and the Alzheimer's Assocation (NIA-AA) criteria. 3. Subjects and their informed persons can complete relevant and follow-up examinations. 4. Subjects or their authorized legal guardians sign the informed consent. Vascular cognitive impairment (VCI) 1. 40 years and older 2. Diagnosis according to the criteria for small vessel VCI, with the following three core elements: 1) Cognitive impairment: memory decline can be highlighted 2) Vascular factors 3) Causal relationship between cognitive impairment and vascular factors 3.Cognitive impairment lasts for 3 months or more, and the CDR global score =0.5 point. 4. All patients need to meet the following MRI criteria: 1. Multiple (=3) small infarcts (3-20 mm in diameter) with or without any degree of white matter lesions (WML); or moderate to severe WML (Fazekas score = 2) , with or without small infarction; or = 1 small infarct in key parts of the cortex, such as: caudate nucleus, globus pallidus, thalamus et al. 2. No WML caused by cortical infarction, watershed infarction, hemorrhage, hydrocephalus, or other causes (such as multiple sclerosis). 3. No hippocampus or entorhinal cortex atrophy, Medial Temporal Lobe Atrophy (MTA)= 1 point. 5. Subjects and their informed persons can complete relevant and follow-up examinations. 6. Subjects or their authorized legal guardians sign the informed consent. Exclusion Criteria: Cognitive normal aging (CN) 1. any disease that can cause cognitive impairment (such as Alzheimer's disease, dementia with Lewy bodies (DLB), frontotemporal dementia (FTLD), Parkinson's disease dementia (PDD), intracranial masses that impair cognition, history of severe brain trauma, normal pressure hydrocephalus, cerebrovascular disease with obvious clinical symptoms, etc. 2. sequelae after previous history of severe central nervous system infection, multiple sclerosis, autoimmune encephalitis, Hashimoto's encephalopathy, etc. 3. previous history of instable epilepsy 4. systemic diseases affect the central nervous system, for abnormal liver and kidney functions (abdominal dialysis, hemodialysis, AST=3× upper limit of normal value (ULN), ALT=3× upper limit of normal value (ULN) or total bilirubin =2×ULN 5. history of hereditary diseases that affect cognitive function (such as Huntington's disease, down syndrome, CADASIL, adrenal leukodystrophy, mitochondrial encephalopathy, etc.) 6. long-term heavy drinking history (alcohol content more than 42 degree liquor, more than 150g/day, alcohol consumption more than 12 months) 7. history of severe pulmonary diseases (COPD, pulmonary encephalopathy) 8. history of serious cardiovascular disease (heart failure, severe hypertension) 9. infection and immune-related diseases affecting the central nervous system (systemic lupus erythematosus, undertreated HIV infection or a history of CNS syphilis infection, etc.) 10. metabolic and endocrine disorders (requiring new treatment or adjustment of current treatment for thyroid dysfunction, folate or vitamin B12 deficiency) 11. unstable psychosis or long-term use of antipsychotic drugs (more than 6 months) 12. history of malignant tumors (tumors of nervous system and other sites) active for nearly 1 year 13. contraindications for MRI (e.g. pacemakers, stents, claustrophobia, etc.) or do not cooperate or cannot carry out PET examination 14. uneducated illiterates 15. hearing impairment, visual impairment and poor coordination 16. withdraw or reject the study Subjective cognitive impairment (SCI) and Mild cognitive impairment (MCI) 1. With history of stroke and a neurological focal sign, the imaging findings are consistent with cerebral vascular disease (Fazekas score = 2 points). 2. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.). 3. Other systemic diseases that can cause cognitive impairment(such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.). 4. Mental and neurodevelopmental retardation. 5. Other diseases known to cause cognitive impairment. 6. Contraindications to nuclear magnetics. 7. Suffering from a disease that cannot be combined with cognitive examination. 8. Refuse to draw blood. 9. Refuse to sign the informed consent at baseline Alzheimer's disease (AD) 1. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.). 2. Other systemic diseases that can cause cognitive impairment(such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.). 3. Mental and neurodevelopmental retardation. 4. Other diseases known to cause cognitive impairment. 5. Contraindications to nuclear magnetics. 6. Suffering from a disease that cannot be combined with cognitive examination. 7. Refuse to draw blood. 8. Refuse to sign the informed consent at baseline Vascular cognitive impairment (VCI) 1. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.). 2. Other systemic diseases that can cause cognitive impairment(such as liver, renal, and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.). 3. Other diseases known to cause cognitive impairment. 4. Hereditary or inflammatory small vessel disease, such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). 5. Contraindications to nuclear magnetics. 6. Refuse to draw blood. 7. Refuse to sign the informed consent at baseline

Study Design


Intervention

Other:
None of intervention
None of intervention

Locations

Country Name City State
China Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang
China Zhejiang Lishui central Hospital Lishui Zhejiang

Sponsors (3)

Lead Sponsor Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University The Central Hospital of Lishui City, Zhejiang Rehabilitation Center

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Prevalence, incidence of cognitive impairment caused by neurological disease such as AD, VCI and other types of dementia All of the participants will be evaluated by cognitive assessment scale annually. 5 years
Primary The conversion rate of normal aging to SCI, MCI and AD All of the participants will be evaluated by cognitive assessment scale annually. 5 years
Primary The fluid biomarkers for normal aging, SCI, MCI and AD diagnosis Cerebrospinal fluid, plasma, saliva and urine biomarkers included Aß42, Aß40, phosphated tau and total tau, and other novel biomarkers. 5 years
Primary The imaging biomarkers for normal aging, MCI and AD diagnosis Imaging biomarkers included cerebral atrophy, amyloid and tau deposition of whole brain or hippocampus, glucose metabolism and other novel biomarkers. 5 years
Primary Gut microbiota Fecal microbiome will be analyzed by 16S rRNA gene sequencing and metagenome sequencing. 5 years
Primary Gait Gait characteristics such as stride-to-stride variability of stride time, and gait speed were evaluated by 3D gait detection. 5 years
See also
  Status Clinical Trial Phase
Completed NCT04044495 - Sleep, Rhythms and Risk of Alzheimer's Disease N/A
Completed NCT04079803 - PTI-125 for Mild-to-moderate Alzheimer's Disease Patients Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT04520698 - Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease N/A
Active, not recruiting NCT04606420 - Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease N/A
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Terminated NCT03672474 - REGEnLIFE RGn530 - Feasibility Pilot N/A
Completed NCT03430648 - Is Tau Protein Linked to Mobility Function?
Recruiting NCT05557409 - A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation Phase 3
Recruiting NCT05288842 - Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Recruiting NCT04949750 - Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease N/A
Completed NCT06194552 - A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07 Phase 1
Completed NCT03239561 - Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants Early Phase 1
Completed NCT03184467 - Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients Phase 2
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Terminated NCT03487380 - Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT05328115 - A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease Phase 1
Completed NCT05562583 - SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support N/A